Twin Gains For Novartis In India Ribociclib, Ceritinib Patent Cases
Executive Summary
Novartis gains upper hand for now, staving off challenge to patents on its oncology drugs ribociclib and ceritinib in India by seasoned opponent Natco, though things appear far from over in the case.
You may also be interested in...
Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component
Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component
Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
Deciphering E-Pharmacy Discounts For Novartis’s Ceritinib In India
Novartis’s anticancer Spexib was being offered at a hefty 69% discount to patients in India, highlighting what some experts suggest is the striking pricing structure and business practices at e-pharmacies in the country.